What changed: Advanced cutaneous squamous cell carcinoma
Every dated change on the records linked to Advanced cutaneous squamous cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval2Regulatory1Trial result2Guideline1Milestone6This record1
September 2026 · 1
2025 · 2
- 2025GuidelineAdvanced cutaneous squamous cell carcinomaGuideline C-POST (NEJM 2025): Adjuvant after surgery and radiotherapy
Cemiplimab for high-risk disease (C-POST, 2025).
- 2025MilestoneCemiplimabC-POST: adjuvant cemiplimab cuts recurrence after surgery and radiotherapy
A milestone in how this cancer is treated.
2024 · 2
2022 · 1
2020 · 2
September 2018 · 1
2018 · 3
- 2018ApprovalCemiplimabCemiplimab approved in US
Advanced cutaneous squamous cell carcinoma
- 2018Trial resultEMPOWER-CSCC-1EMPOWER-CSCC-1 reported
Objective response 47% in the metastatic group; 46% in the pooled analysis of 193 patients with 16% complete responses.
- 2018MilestoneEMPOWER-CSCC-1EMPOWER-CSCC-1: cemiplimab is the first approved systemic therapy
A milestone in how this cancer is treated.